NYSE:RMD

ResMed Inc. (RMD)

208.56
-5.73 (2.67%)
as of Jul 30, 2026, 8:00:00 pm Market Open.
30 watching
0
Investor Insights
star iconJul 31, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

ResMed Inc. (RMD-N) has emerged as a promising investment with a significant upside noted in recent reviews. Experts highlight the company's dominance in the CPAP machine market, underscoring the low likelihood of customers switching to competitors. Notably, ResMed has reported strong earnings performance over the last four quarters, with a significant year-over-year EPS increase of 37.09%. The company's current P/E ratio of 31.2 is considerably lower than its previous high of 74.5, suggesting potential for further growth. While the dividend yield of 0.76% indicates that ResMed is more focused on growth rather than providing income, its high return on equity of 25.81% positions it favorably within the medical equipment sector, especially given that the average ROE in this industry is only 9.66%.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
Philips, PHG
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 20/25, Up 10.1%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with RMD has triggered its stop at $244.  To remain disciplined, we recommend covering the position at this time.  

PAST TOP PICK
(A Top Pick Oct 11/24, Up 14%)

It has an unaddressed market for CPAP machines. It is a dominant player since people are not likely to change to another product. Weight loss drugs can be part of a total package.

premiumPremium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

ResMed has beaten earnings four straight quarters, and its 31.2x PE is nowhere near its 2021 high of 74.5x. However, the street projects a lower future PE of 27.69x. The most recent EPS of $8.91 was 37.09% more than the previous year. Its ROE of 25.81% ranks among the highest in medical equipment where the average is 9.66%. A bonus is that the company operates within the U.S., so is protected from tariffs. Paying a dividend of only 0.76%, ResMed is one for growth, not income.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 20/25, Up 22.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with RMD is progressing well.  To remain disciplined, we recommend trailing up the stop (from $230) to $244 at this time.  

BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

RMD has been showing positive momentum recently, it is nearing in on its all-time highs, and forward margin expansion is expected to be quite positive. Analyst estimates are trending higher, its margins have been growing, and it generats strong free cash flow, which is partly used for dividends, buybacks, and growing the balance sheet. It is trading at a reasonable valuation of 25X forward earnings, and it has structural tailwinds. We would be comfortable buying the name here today for a long-term hold.
Unlock Premium - Try 5i Free 

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 20/25, Up 11.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with RMD is progressing well.  To remain disciplined, we recommend trailing up the stop (from $209) to $230 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 20/25, Up 7.1%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with RMD is progressing well.  To remain disciplined, we recommend trailing up the stop (from $190) to $209 at this time.  

PARTIAL BUY

They operate purely domestically, so are safe from tariffs. They report a solid quarter Wednesday and got exempted from tariffs. It could have more room to run.

BUY

His reservations about their GLP-1 business were misplaced, and the company is doing quite well.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

RMD provides cloud based digital medical devices to assist with sleep and respiratory monitoring and treatment — a steady and reliable business model.  It trades at 26x earnings and supports a respectable ROE of 25%.  We like that cash reserves are growing, while debt is retired and shares bought back.  We recommend setting a stop-loss at $190, looking to achieve $271 — upside potential of 22%.  Yield 1.0%

(Analysts’ price target is $271.71)
TOP PICK

Gagdets like Goggle Watch have shown people how poorly they sleep. Resmed makes sleep apnea machines, which sees big, growing demand, and they hold 90% of the market.

(Analysts’ price target is $241.48)
BUY ON WEAKNESS

Shares have been knocked down. Good management.

BUY
They make sleep apnea machines, but now make ventilators during quarter. Last-October they just reported a super quarter that pushed the stock from $180 to $220 in days. It's pulled back to $211 because of positive vaccine news. It'll get a boost from their sleep apnea machines after Covid when people will visit their doctors again.
PAST TOP PICK
(A Top Pick Sep 25/18, Up 18%) They had a big correction in January and he got stopped out. Pity, because he missed that big run after January. We work on sleep apnea devices, which is a demographic play. A great name. Wishes he still owned it.
TOP PICK

18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75)

Showing 1 to 15 of 22 entries

ResMed Inc. (RMD) Frequently Asked Questions

What is ResMed Inc. stock symbol?

ResMed Inc. is a American stock, trading under the symbol RMD (previously RMD-N on Stockchase) on the New York Stock Exchange (RMD). It is usually referred to as NYSE:RMD or RMD

Is ResMed Inc. a buy or a sell?

In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on RMD (previously RMD-N on Stockchase). 4 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for ResMed Inc..

Is ResMed Inc. a good investment or a top pick?

ResMed Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-04. Read the latest stock experts ratings for ResMed Inc..

Why is ResMed Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for ResMed Inc..

Is ResMed Inc. worth watching?

ResMed Inc. is followed by 30 investors on Stockchase and is a trending stock that is worth watching.

What is ResMed Inc. stock price?

On 2026-07-30, ResMed Inc. (RMD) stock closed at a price of $208.56.

Star iconStar iconStar iconStar iconStar icon
5(4)
Based on 4 expert opinions: 4 buy 0 hold 0 sell